Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

Nike Beaubier, Robert Tell, Denise Lau, Jerod Parsons, Stephen J. Bush, Jason Perera, Shelly Sorrells, Timothy Baker, Alan L. Chang, Jackson Michuda, Catherine Iguartua, Shelley MacNeil, Kaanan P. Shah, Philip P. Ellis, Kimberly Yeatts, Brett Mahon, Timothy Taxter, Martin Bontrager, Aly A. Khan, Robert Huether, Eric Lefkofsky, Kevin P. WhiteOncotarget 2019 · DOI

Abstract

We developed and clinically validated a hybrid capture next generation sequencing assay to detect somatic alterations and microsatellite instability in solid tumors and hematologic malignancies. This targeted oncology assay utilizes tumor-normal matched samples for highly accurate somatic alteration calling and whole transcriptome RNA sequencing for unbiased identification of gene fusion events. The assay was validated with a combination of clinical specimens and cell lines, and recorded a sensitivity of 99.1% for single nucleotide variants, 98.1% for indels, 99.9% for gene rearrangements, 98.4% for copy number variations, and 99.9% for microsatellite instability detection. This assay presents a wide array of data for clinical management and clinical trial enrollment while conserving limited tissue.

Introduction

Precision medicine relies on identifying specific "drivers" of a patient's tumor to select targeted therapies. However, clinicians face several hurdles: tissue scarcity, the difficulty of distinguishing somatic mutations from germline variants, and detection blind spots for complex gene rearrangements. The Tempus xT assay addresses these challenges by integrating DNA and RNA sequencing into a single workflow that utilizes tumor-normal matching to ensure high-confidence results.

Methodology

The xT assay employs a hybrid capture NGS approach, interrogating 595 cancer-related genes at a high depth of coverage (500x). By sequencing the patient’s healthy tissue (blood or saliva) alongside the tumor, the assay filters out benign inherited variants, significantly reducing false-positive somatic calls. Unlike many panels that use DNA tiling for fusions, xT uses whole-transcriptome RNA sequencing to identify gene fusion events across the entire transcriptome, providing an unbiased view of structural rearrangements. Additionally, the pipeline calculates Tumor Mutational Burden (TMB), determines Microsatellite Instability (MSI) status, and performs HLA typing and neoantigen prediction.

Validation and Accuracy

The assay was validated using 265 clinical specimens and reference standards with known Variant Allele Fractions (VAF). Results were compared against the larger Tempus xO assay (1,711 genes) to ensure concordance.

Correlation of allelic fractions between the xT and xO assays.

The high correlation ($r^2 = 0.921$) between the xT and xO assays demonstrates the reliability of the targeted panel in capturing the genomic landscape of the tumor.

Sensitivity and Detection Limits

Validation metrics for the xT assay are high across all categories, with sensitivities exceeding 98% for mutations, fusions, and copy number changes. Specifically, the assay achieved 99.1% sensitivity for SNVs and 98.1% for indels.

Detection of INDELs and SNPs across dilution series.

The assay consistently detected SNVs down to a 5% VAF and MSI status down to 20-30% tumor purity. Specificity was measured at greater than 99.9%.

Clinical Utility and Discussion

In a cohort of 952 patients, 88.6% had at least one biologically relevant alteration, proving the assay's high yield in a clinical setting. The inclusion of HLA typing and neoantigen prediction moves the assay from a simple mutation detector to a comprehensive tool for immuno-oncology.

While highly sensitive, detection of MSI status becomes challenging when tumor purity drops below 30%. Future work will likely focus on how these integrated genomic and transcriptomic profiles correlate with long-term patient outcomes in large-scale clinical trials.

Summary updated

Abstract

We developed and clinically validated a hybrid capture next generation sequencing assay to detect somatic alterations and microsatellite instability in solid tumors and hematologic malignancies. This targeted oncology assay utilizes tumor-normal matched samples for highly accurate somatic alteration calling and whole transcriptome RNA sequencing for unbiased identification of gene fusion events. The assay was validated with a combination of clinical specimens and cell lines, and recorded a sensitivity of 99.1% for single nucleotide variants, 98.1% for indels, 99.9% for gene rearrangements, 98.4% for copy number variations, and 99.9% for microsatellite instability detection. This assay presents a wide array of data for clinical management and clinical trial enrollment while conserving limited tissue.
BibTeX
@inproceedings{beaubier2019clinical,
  author = {Nike Beaubier and Robert Tell and Denise Lau and Jerod Parsons and Stephen J. Bush and Jason Perera and Shelly Sorrells and Timothy Baker and Alan L. Chang and Jackson Michuda and Catherine Iguartua and Shelley MacNeil and Kaanan P. Shah and Philip P. Ellis and Kimberly Yeatts and Brett Mahon and Timothy Taxter and Martin Bontrager and Aly A. Khan and Robert Huether and Eric Lefkofsky and Kevin P. White},
  title = {{Clinical validation of the tempus xT next-generation targeted oncology sequencing assay}},
  booktitle = {Oncotarget},
  year = {2019},
  doi = {10.18632/oncotarget.26797},
}
Figure